Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

Exclusion Criteria

• •Subjects who participated in sanofi pasteur Study MTA17 Stage I (a subset of subjects from Study 603-02 who had been recruited for the follow-up challenge study)
• •History of documented invasive meningococcal disease
• •Received any other meningococcal vaccine
• •Received any vaccine in the 28-day period prior to enrollment
• •Received antibiotic therapy within the 72 hours prior to collection of a blood sample
• •Actively enrolled or scheduled to be enrolled in another clinical study
• •Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system)
• •Known or suspected impairment of immunologic function
• •Acute medical illness with or without fever within 72 hours or an oral temperature ≥ 100.4°F (≥ 38.0°C) at the time of inclusion
• •Scheduled to receive any vaccination in the 7-day or 14-day period after enrollment
• •Administration of immune globulin, other blood products, or corticosteroid within 8 weeks (56 days) of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
• •Personal of family history of Guillain-Barres Syndrome
• •Suspected or known hypersensitivity to any of the vaccine components
• •Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures
• •Any condition which, in the opinion of the investigator, would pose a health risk to the participant.